BTG3 and celiac disease: Hazard ratio for coeliac disease was 5.24 (95% CI 1.76–15.65) in the total JIA cohort, with further increase in individuals belonging to the ANA positive subgroup (HR 7.22, 95% CI 1.72–30.35) and the subgroup treated with DMARD (HR 9.30, 95% CI 1.70–50.88) (Fig. 4).